publication date: Dec. 6, 2019

NCI Trials

NCI Trials for December 2019

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – 10291

A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Mayo Clinic Cancer Center LAO

Mutter, Robert W.

(507) 284-8227

 

Phase I/II – PBTC-055

Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-Mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-Associated Recurrent or Progressive Gliomas in Children and Young Adults

Pediatric Brain Tumor Consortium

Hoffman, Lindsey M.

(602)9330920

 

Phase II – 10222

A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors

Yale University Cancer Center LAO

Hafez, Navid

(203) 785-3333

 

Phase II – 10284

Phase II Trial of Avelumab (BavencioÆ) with IL-15 in Subjects with Clear-Cell Renal Carcinoma

NCI Center for Cancer Research

Conlon, Kevin C.

(301) 402-2913

 

Phase III – EA2186

A Randomized Phase III Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment NaÔve Metastatic Pancreatic Cancer

ECOG-ACRIN Cancer Research Group

Dotan, Efrat

(215) 728-2500

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.